Nov 25, 2025
Newsroom
PharmaEssentia Announces Publication of Phase 3 SURPASS-ET Results in The Lancet Haematology
Learn MoreNov 11, 2025
Newsroom
PharmaEssentia USA Announces Appointment of Dr. Barry Flannelly as Independent Director
Learn MoreOct 6, 2025
Newsroom
Material Information - Hong Kong Department of Health has Approved the New Drug Registration of BESREMi (Ropeginterferon alfa-2b) for PV
Learn MoreSep 22, 2025
Newsroom
Material Information - Announcement of the U.S. FDA’s Positive Preliminary Comments on the Filing for Expansion of Indication of BESREMi for Essential Thrombocythemia (ET)
Learn MoreSep 18, 2025
Newsroom
Material Information - Announcement on Behalf of PharmaEssentia Japan KK: Filing for an Additional Indication of BESREMi (Ropeginterferon alfa-2b) for ET in Japan
Learn MoreSep 11, 2025
Newsroom
Material Information - The Health Canada has Accepted the New Drug Submission of Ropeginterferon alfa-2b for PV
Learn MoreSep 5, 2025
Newsroom
Material Information - PharmaEssentia Files for an Additional Indication of Besremi (Ropeginterferon alfa-2b) for the Treatment of Essential Thrombocythemia (ET) with TFDA
Learn MoreAug 19, 2025
Newsroom
PharmaEssentia to Participate at Morgan Stanley 23rd Annual Global Healthcare Conference
Learn MoreJul 18, 2025
Newsroom
Material Information - The Company Announces Filing of New Drug Submission of BESREMi (Ropeginterferon alfa-2b) for PV in Canada
Learn MoreJul 16, 2025
Newsroom
Material Information - The China NMPA has Accepted the Marketing Authorization Application of Ropeginterferon alfa-2b for ET
Learn More